Not available
Quote | Agios Pharmaceuticals Inc. (NASDAQ:AGIO)
Last: | $32.69 |
---|---|
Change Percent: | -0.09% |
Open: | $33.47 |
Close: | $32.69 |
High: | $33.71 |
Low: | $32.44 |
Volume: | 538,300 |
Last Trade Date Time: | 05/23/2024 03:00:00 am |
News | Agios Pharmaceuticals Inc. (NASDAQ:AGIO)
– Data from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia to be Presented in Plenary Session – – Additional Presentations to Highlight Quality of Life Data from ENERGIZE and Design of the Phase 3 RISE UP Study of Mitapivat in Sic...
CAMBRIDGE, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that the company is scheduled to present at the BofA Securities 2024 Health Care Conference on T...
Message Board Posts | Agios Pharmaceuticals Inc. (NASDAQ:AGIO)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $AGIO News Article - Agios to Webcast Conference Call of First Quarter 2023 Financial R | whytestocks | investorshangout | 04/13/2023 3:00:57 PM |
whytestocks: $AGIO News Article - Agios Appoints Rahul Ballal and Cynthia Smith to Board of Director | whytestocks | investorshangout | 08/15/2022 3:11:23 PM |
whytestocks: $AGIO News Article - Agios Reports Business Highlights and Second Quarter 2022 Financia | whytestocks | investorshangout | 08/04/2022 3:00:57 PM |
whytestocks: $AGIO News Article - Agios to Webcast Conference Call of Second Quarter 2022 Financial | whytestocks | investorshangout | 07/14/2022 2:40:52 PM |
whytestocks: $AGIO News Article - Agios Appoints Brian Goff as Chief Executive Officer | whytestocks | investorshangout | 07/12/2022 8:50:55 PM |
News, Short Squeeze, Breakout and More Instantly...
Agios Pharmaceuticals Inc. Company Name:
AGIO Stock Symbol:
NASDAQ Market:
Agios Pharmaceuticals Inc. Website:
At the RBC Global Healthcare Conference, held on 14-15 May, RBC’s Healthcare Desk Sector Strategist gauged biotech investor sentime...
– Data from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia to be Presented in Plenary Session – – Additional P...
– Data from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia to be Presented in Plenary Session – – Additional Presentations to Highlight Quality of Life Data from ENERGIZE and Design of the Phase 3 RISE UP Study of Mitapivat in Sic...